-
公开(公告)号：US20150306060A1
公开(公告)日：2015-10-29
申请号：US14637081
申请日：2015-03-03
IPC分类号： A61K31/25
CPC分类号： A61K31/25 , A61K31/215
摘要： Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.
摘要翻译： 公开了哺乳动物高胆固醇血症的治疗管理方法。 更具体地说，本发明涉及一种降低哺乳动物血液中高水平循环胆固醇（高胆固醇血症）的方法，所述方法包括向所述哺乳动物施用治疗有效量的贻贝A以产生（i ）降低总胆固醇含量; （ii）降低低密度脂蛋白（LDL）和极低密度脂蛋白（VLDL）的浓度; （iii）增加高密度脂蛋白（HDL）的浓度和（iv）降低血清甘油三酸酯的浓度。
-
公开(公告)号：US20150306059A1
公开(公告)日：2015-10-29
申请号：US14259404
申请日：2014-04-23
IPC分类号： A61K31/25
CPC分类号： A61K31/25 , A61K31/215
摘要： Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.
-
公开(公告)号：US20210220290A1
公开(公告)日：2021-07-22
申请号：US17151121
申请日：2021-01-16
摘要： The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.
-
4.发明授权Composition comprising scirpusin A and scirpusin B and anti-adipogenesis/anti-obesity potential thereof 有权组合物，其包含鞘氨醇蛋白A和柔霉素B及其抗脂肪生成/抗肥胖潜力公开(公告)号：US09387193B2
公开(公告)日：2016-07-12
申请号：US13944634
申请日：2013-07-17
申请人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey
发明人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey
IPC分类号： A61K31/343 , A61K36/8905
CPC分类号： A61K31/343 , A61K36/8905
摘要： Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of Cyperus rotundus.
摘要翻译： 本发明公开了一种组合物，其中含有柔霉素A和柔霉素B及其抗肥胖潜力。 还公开了使用包含灵敏蛋白A和柔红霉素B的组合物来抑制脂肪生成的方法。本发明还公开了使用包含巩螺素A和柔红霉素B的组合物来治疗哺乳动物肥胖的方法。此外，本发明还涉及一种方法 通过生物活性引导分离莎草莎草根茎，获得包含A.Scirpusin A和Scirpusin B和B.piceatannol及其二聚体scirpusin A和scirpusin B的组合物。
-
公开(公告)号：US20200268822A1
公开(公告)日：2020-08-27
申请号：US16386376
申请日：2019-04-17
摘要： The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w Withania somnifera extract, 12-18% w/w Mucana pruriens extract, 5-10% w/w Coleus forskolii extract, 12-18% w/w Kaempferia parviflora extract, 0.1-2% w/w Piper nigrum extract, for use as an aphrodisiac.
-
公开(公告)号：US20170128410A1
公开(公告)日：2017-05-11
申请号：US14936830
申请日：2015-11-10
IPC分类号： A61K31/352 , C12N5/077 , G01N33/50
CPC分类号： A61K31/352 , A61K35/35 , C12N5/0653 , C12N2501/01 , C12N2506/13 , G01N33/5044 , G01N2333/51 , G01N2333/515
摘要： Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.
-
7.发明申请COMPOSITION COMPRISING SCIRPUSIN A AND SCIRPUSIN B AND ANTI-OBESITY POTENTIAL THEREOF 有权包含SCIRPUSIN A和SCIRPUSIN B的组合物及其抗氧化潜能公开(公告)号：US20150238438A1
公开(公告)日：2015-08-27
申请号：US14705111
申请日：2015-05-06
申请人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey , Suresh Karri
发明人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey , Suresh Karri
IPC分类号： A61K31/015 , A61K36/8905
CPC分类号： A61K36/8905 , A61K31/015 , A61K31/343
摘要： Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stiibenes.
摘要翻译： 公开的是使用包含标准化以含有5％总胆固醇的莎草莎草提取物的乙酸乙酯部分的物质组合物来控制肥胖症和高胆固醇血症的方法。
-
公开(公告)号：US20220347120A1
公开(公告)日：2022-11-03
申请号：US17732655
申请日：2022-04-29
IPC分类号： A61K31/12 , A61K9/00 , A61P15/08 , A61K9/20 , A61K9/16 , A61K47/26 , A61K47/42 , A61K47/12 , A61K47/10 , A61K9/48
摘要： The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.
-
公开(公告)号：US20210220291A1
公开(公告)日：2021-07-22
申请号：US17151172
申请日：2021-01-17
IPC分类号： A61K31/122 , A61K31/09 , A61P11/00
摘要： The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.
-
公开(公告)号：US11052125B2
公开(公告)日：2021-07-06
申请号：US16396902
申请日：2019-04-29
IPC分类号： A61K36/8905 , A61K36/38 , A61K36/67 , A61P3/04 , A61K36/53
摘要： The present invention discloses a composition comprising extracts of Cyperus rotundus, standardized to contain 3-5% w/w total stilbenes, extracts of Garcinia sp., standardized to contain 20% w/w garcinol and extracts of Coleus forskohlii standardized to contain not less than 10% w/w forskolin for the therapeutic management of diet induced obesity and weight gain and related conditions like liver dysfunction, NASH, NAFLD, liver cirrhosis, hypercholesterolemia, hyperlipidemia, kidney dysfunction by bringing about a reduction in body weight, increasing lean body mass and by normalizing the levels of liver enzymes, kidney markers and circulating lipids.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.022 秒)